EVALUATION OF EFFICACY AND SAFETY OF NIGELLA SATIVA OIL SUPPLEMENTATION IN PATIENTS OF CHRONIC KIDNEY DISEASE
Abstract
ABSTRACT
Objective: To evaluate efficacy and safety of add-on therapy of Nigella sativa oil in patients of stage 3 and 4 of chronic kidney disease (CKD).
Materials and Methods: The study was conducted in a tertiary care center of north India in stage 3 and 4 patients of CKD. It was a prospective,
comparative, and open label study. Patients were randomly divided into two interventional groups. Group I (Control) received conservative
management of CKD while Group II (Test) received conservative management along with N. sativa oil (2.5 mL, per orally, once daily) for 12 weeks.
Hemogram and renal function tests were done, and adverse events were recorded at 0, 6, and 12 weeks of treatment.
Results: After 12 weeks of treatment, there was a progressive improvement in clinical features and biochemical parameters in both the groups, but it
was more marked in the test group compared to control group. Both groups showed gradual improvement in the biochemical parameters as compared
to their pre-treated values which were more marked in N. sativa oil supplemented group. There was a reduction in blood glucose, blood urea, serum
creatinine, and 24-hr total urine protein. There was an increase in hemoglobin, 24-hr total urine volume, and glomerular filtration rate.
Conclusion: N. sativa oil supplementation along with conservative management is efficacious and safe in averting the progression of disease in stage 3
and 4 patients of CKD.
Keywords: Chronic kidney disease, Nigella sativa oil, End-stage renal disease, Glomerular filtration rate.
Downloads
References
REFERENCES
National Kidney Foundation. K/DOQI clinical practice guidelines for
chronic kidney disease: Evaluation, classification, and stratification.
Am J Kidney Dis 2002;39 2 Suppl 1:S1-266.
Levey AS, Atkins R, Coresh J, Cohen EP, Collins AJ, Eckardt KU, et al.
Chronic kidney disease as a global public health problem: Approaches
and initiatives - A position statement from Kidney Disease Improving
Global Outcomes. Kidney Int 2007;72:247-59.
Singh AK, Farag YM, Mittal BV, Subramanian KK, Reddy SR,
Acharya VN, et al. Epidemiology and risk factors of chronic kidney
disease in India - results from the SEEK (Screening and Early
Evaluation of Kidney Disease) study. BMC Nephrol 2013;14:114.
Sakhuja V, Sud K. End-stage renal disease in India and Pakistan: Burden
of disease and management issues. Kidney Int Suppl 2003;(83)S115-8.
Chang JH, Kim DK, Park JT, Kang EW, Yoo TH, Kim BS, et al.
Influence of ketoanalogs supplementation on the progression in
chronic kidney disease patients who had training on low-protein diet.
Nephrology (Carlton) 2009;14:750-7.
Fouque D, Laville M, Boissel JP. Low protein diets for chronic
kidney disease in non-diabetic adults. Cochrane Database Syst Rev
;(2):CD001892.
El-Shamy KA, Mosa MM, El-Nabarawy SK, El-Qattan GM. Effect
of Nigella sativatea in type 2-diabetic patients as regards glucose
homeostasis, liver and kidney functions. J Appl Sci Res 2011;7:2524-34.
Mohtashami R, Amini M, Huseini HF, Ghamarchehre M, Sadeqhi
Z, Hajiagaee R, et al. Blood glucose lowering effects of Nigella
sativa L. seeds oil in healthy volunteers: A randomized, double-blind,
placebo-controlled clinical trial. J Med Plants 2011;10:90-4.
Nickavar B, Mojab F, Javidnia K, Amoli MA. Chemical composition of
the fixed and volatile oils of Nigella sativa L. from Iran. Z Naturforsch C
;58:629-31.
Salem ML. Immunomodulatory and therapeutic properties of the
Nigella sativa L. seed. Int Immunopharmacol 2005;5(13-14):1749-70.
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al.
A method for estimating the probability of adverse drug reactions. Clin
Pharmacol Ther 1981;30(2):239-45.
Hartwig SC, Siegel J, Schneider PJ. Preventability and severity
assessment in reporting adverse drug reactions. Am J Hosp Pharm
;49(9):2229-32.
Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of
diabetes: Estimates for the year 2000 and projections for 2030. Diabetes
Care 2004;27(5):1047-53.
Gupta R. Trends in hypertension epidemiology in India. J Hum
Hypertens 2004;18(2):73-8.
Kher V. End-stage renal disease in developing countries. Kidney Int
;62(1):350-62.
Yusof HM, Ling LP, Muhamad S, Suhaimin N. Effect of Nigella sativa
and honey mixture (NSxH) on cardiovascular risk factors in healthy
adults. UMT 11
International Annual Symposium on Sustainability
Science and Management, Terengganu, Malaysia; 2012.
th
Shah AS, Khan GM, Badshah A, Shah SU, Shah KU, Mirza SA, et al.
Nigella sativa provides protection against metabolic syndrome. Afr J
Biotechnol 2012;11:10919-25.
Fallah Huseini H, Amini M, Mohtashami R, Ghamarchehre ME,
Sadeqhi Z, Kianbakht S, et al. Blood pressure lowering effect of
Nigella sativa L. seed oil in healthy volunteers: A randomized,
double-blind, placebo-controlled clinical trial. Phytother Res
;27(12):1849-53.
Dehkordi FR, Kamkhah AF. Antihypertensive effect of Nigella sativa
seed extract in patients with mild hypertension. Fund Clin Pharmacol
;22(4):447-52.
Tekeoglu I, Dogan A, Ediz L, Budancamanak M, Demirel A. Effects of
thymoquinone (volatile oil of black cumin) on rheumatoid arthritis in
rat models. Phytother Res 2007;21:895-7.
Meziti A, Meziti H, Boudiaf K, Budancamanak M, Demirel A.
Polyphenolic profile and antioxidant activities of Nigella sativa
seed extracts in vitro and in vivo. World Acad Sci Eng Technol
;64(6):24-32.
Bayrak O, Uz E, Bayrak R, Turgut F, Atmaca AF, Sahin S, et al.
Curcumin protects against ischemia/reperfusion injury in rat kidneys.
World J Urol 2008;26(3):285-91.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.